Literature DB >> 11122833

Molecular biology of leukemia.

A Jakubowiak1, J Cammenga, R Sokolic, S Alvarez, G Jackson, C Hedvat, S D Nimer.   

Abstract

Identification and characterization of leukemia-related chromosomal translocations have had significant impact on all aspects of the management of acute leukemia, including its diagnosis, assignment of prognosis, and development of an appropriate treatment plan. Several genes are recurrent targets of chromosomal abnormalities, suggesting that they play a key role in leukemogenesis. Significant progress has been made to define potentially unifying molecular mechanisms of leukemic transformation. Hopefully, these findings will provide the basis for molecularly targeted therapies for leukemia.

Entities:  

Mesh：

Year:  2000        PMID： 11122833     DOI： 10.1007/s11912-000-0083-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.945


  62 in total

1.  Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein.

Authors:  R Fenrick; J M Amann; B Lutterbach; L Wang; J J Westendorf; J R Downing; S W Hiebert
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

2.  Molecular insights into PEBP2/CBF beta-SMMHC associated acute leukemia revealed from the structure of PEBP2/CBF beta.

Authors:  M Goger; V Gupta; W Y Kim; K Shigesada; Y Ito; M H Werner
Journal:  Nat Struct Biol       Date:  1999-07

3.  HOXA9 forms triple complexes with PBX2 and MEIS1 in myeloid cells.

Authors:  W F Shen; S Rozenfeld; A Kwong; L G Köm ves; H J Lawrence; C Largman
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

Review 4.  Transcription factors, normal myeloid development, and leukemia.

Authors:  D G Tenen; R Hromas; J D Licht; D E Zhang
Journal:  Blood       Date:  1997-07-15       Impact factor: 22.113

5.  The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells.

Authors:  M Kurokawa; K Mitani; Y Imai; S Ogawa; Y Yazaki; H Hirai
Journal:  Blood       Date:  1998-12-01       Impact factor: 22.113

6.  The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B.

Authors:  R Frank; J Zhang; H Uchida; S Meyers; S W Hiebert; S D Nimer
Journal:  Oncogene       Date:  1995-12-21       Impact factor: 9.867

7.  Fusion of ETV6 to the caudal-related homeobox gene CDX2 in acute myeloid leukemia with the t(12;13)(p13;q12).

Authors:  A Chase; A Reiter; L Burci; G Cazzaniga; A Biondi; J Pickard; I A Roberts; J M Goldman; N C Cross
Journal:  Blood       Date:  1999-02-01       Impact factor: 22.113

8.  Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia.

Authors:  T Nakamura; D A Largaespada; M P Lee; L A Johnson; K Ohyashiki; K Toyama; S J Chen; C L Willman; I M Chen; A P Feinberg; N A Jenkins; N G Copeland; J D Shaughnessy
Journal:  Nat Genet       Date:  1996-02       Impact factor: 38.330

9.  Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.

Authors:  V Gelmetti; J Zhang; M Fanelli; S Minucci; P G Pelicci; M A Lazar
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

10.  Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors.

Authors:  D Levanon; R E Goldstein; Y Bernstein; H Tang; D Goldenberg; S Stifani; Z Paroush; Y Groner
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.